<DOC>
	<DOCNO>NCT00082459</DOCNO>
	<brief_summary>The goal trial determine safety HSPPC-96 route administration achieve good response vaccine . HSPPC-96 immunotherapeutic agent make individual patient 's tumor .</brief_summary>
	<brief_title>Trial Compare Routes Administration Investigational , Personalized , Therapeutic Cancer Vaccine Oncophage ( HSPPC-96 ) Patients With Metastatic Renal Cell Carcinoma</brief_title>
	<detailed_description>The goal trial determine safety HSPPC-96 route administration achieve good response vaccine . HSPPC-96 immunotherapeutic agent make individual patient 's tumor . The study conduct Houston , Texas patient enrol one two treatment arm . The two treatment arm either subcutaneous injection intradermal injection , HSPPC-96 . To treated HSPPC-96 patient must undergo surgery remove kidney tumor portion tissue send Antigenics ' manufacturing facility processing .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<criteria>Suspected metastatic renal cell carcinoma ( AJCC Stage IV ) intact primary tumor No previous therapy metastatic renal cell carcinoma Measurable disease ( RECIST criterion ) Primary tumor great equal 7cm CT MRI ECOG performance status 01 At least 18 year old Life expectancy &gt; 3 month Adequate cardiac function ( NYHA III ) Not pregnant Provide write informed consent Absence multiple liver metastasis , brain threaten bone metastasis ( axial skeleton and/or pathological feature ) Planned complete nephrectomy History primary secondary immunodeficiency , patient use systemic corticosteroid cyclosporin A Other cancer ( include renal cell carcinoma ) within last five year ( exception adequately treat conebiopsied situ carcinoma cervix uteri basal squamous cell carcinoma skin ) Embolization renal artery prior nephrectomy Active , uncontrolled infection serious medical illness , prevent study completion , opinion Principal Investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Kidney Cancer</keyword>
	<keyword>Renal</keyword>
	<keyword>Tumor</keyword>
	<keyword>Immunotherapy</keyword>
</DOC>